DSIP
Recherche publiée et base de preuves
Delta sleep-inducing peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 from cerebral venous blood of sleep-induced rabbits. Despite five decades of study, no DSIP gene, precursor protein or receptor has been identified, and the peptide's status as an endogenous sleep factor remains contested. Human work is concentrated in the 1980s and early 1990s and includes small double-blind studies in insomnia, chronic pain and opioid withdrawal with inconsistent results; recent research is almost entirely rodent work on stroke, stress and drug-delivery constructs.
- Le DSIP est un peptide de neuf acides aminés isolé du sang cérébral de lapin en 1977.
- De petites études humaines des années 1980 et 1990 ont rapporté des résultats variables.
- Aucun récepteur ou gène du DSIP n'a été identifié et son rôle naturel est contesté.
36 études · 1 depuis 2023 · plus récente 2024
- Études citées
- 36
- Publiées 2023+
- 1
- Article le plus récent
- 2024
- Dernière révision
- oct. 2026
Thèmes récurrents dans la littérature
- slow-wave sleep
- endogenous sleep factor hypothesis
- blood-brain barrier transport
- stress and HPA axis
- opioid withdrawal
- antioxidant and geroprotective effects
- unidentified receptor
Identifiants du composé
- CAS
- 62568-57-4
- PubChem
- 68816
Non recommandé par un comité consultatif de la FDA.
Le 23–24 July 2026, le comité consultatif sur la préparation pharmaceutique de la FDA a examiné DSIP, entendu sous le nom emideltide, pour la liste 503A Bulks et a refusé de recommander son ajout lors d'un vote rapporté de 6–7 with one abstention. The only one of the seven peptides the committee declined to recommend. It was heard under the name emideltide.
Ce n'est pas une approbation. Le comité conseille ; il ne décide pas. La recommandation n'est pas contraignante, la FDA n'a pas terminé la réglementation qui changerait formellement quoi que ce soit, et l'inclusion dans la liste 503A Bulks n'équivaut pas à l'approbation FDA d'un médicament. La liste régit également la préparation pharmaceutique pour les patients, qui est une activité distincte de la fourniture à usage de recherche uniquement.
Ce que le vote consultatif de juillet 2026 a réellement accompli décrit le processus, les autres composés examinés et les quatre choses que le vote est régulièrement mal interprété comme signifiant.
Ce qu'est DSIP, chimiquement.
- Formule moléculaire
- C35H48N10O15
- Masse moléculaire
- 848.8 g/mol
- Numéro CAS
- 62568-57-4
- PubChem CID
- 68816
Emideltide
Ces chiffres proviennent de la fiche PubChem pour ce composé et décrivent la base libre. Le peptide lyophilisé est normalement fourni sous forme de sel d'acétate ou de trifluoroacétate et contient de l'eau résiduelle, donc la masse de poudre dans un flacon ne correspond pas à la quantité suggérée par la masse moléculaire ci-dessus. La pureté chromatographique sur un certificat d'analyse ne résout pas cette différence non plus — comment lire un certificat d'analyse explique pourquoi.
36 études publiées.
Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.
- 01Clinique humaine2009
Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
Pomfrett CJ, et al. · European Journal of Anaesthesiology · randomised controlled trial, 24 female ASA I-II patients; intravenous DSIP 25, 50 or 100 nmol/kg vs saline during isoflurane anaesthesia
DSIP increased heart rate, decreased heart rate variability and, contrary to the hypothesis, reduced delta rhythm and increased bispectral index at 25 nmol/kg. The authors concluded DSIP lightened rather than deepened anaesthetic depth.
- 02Clinique humaine2004· Russian (English abstract)
[Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide].
Odin VI, et al. · Adv Gerontol · uncontrolled pilot study, n=11 elderly patients with diabetes (mean age 66.3); course of the DSIP-containing drug Deltaran, assessed before and 60 days after starting
After treatment, SCAG-scale scores improved for recent memory (p=0.003), depressed mood (p=0.019), emotional lability (p=0.002) and anxiety, sleep quality improved, post-load glycaemia fell (p=0.033) and basal and stimulated growth hormone fell. There was no control group.
- 03Clinique humaine2001
Intranasal administration of delta sleep-inducing peptide increases P300.
Hruz P, et al. · J Clin Psychopharmacol · research letter on intranasal DSIP and the P300 event-related potential; design and sample size not available in the registry record
The title reports that intranasal administration of DSIP increased P300. Results are not available in the abstract (PubMed holds no abstract).
- 04Clinique humaine1998
Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial
Backmund M, Meyer K, Rothenhaeusler HB, Soyka M · Journal of Clinical Psychopharmacology · open clinical trial in opioid detoxification
This open-label report described use of DSIP during opioid detoxification. It was published as a short communication without a control group.
- 05Clinique humaine1995
Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy
Vgontzas AN, Friedman TC, Chrousos GP, Bixler EO, Vela-Bueno A, Kales A · Peptides · cross-sectional plasma sampling: 9 sleep apnoea patients, 10 narcolepsy patients, 11 normal controls, plus a second cohort
Morning plasma DSIP-like immunoreactivity did not differ significantly between sleep apnoea patients, narcolepsy patients and controls. The findings did not support single plasma DSIP measures as a disease marker.
- 06Clinique humaine1995
Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion.
Späth-Schwalbe E, et al. · Psychoneuroendocrinology · placebo-controlled intravenous infusion studies in healthy young men: CRH-stimulation experiment (n=5 in each condition) and meal-related secretion experiment (n=10)
ACTH and cortisol responses to human CRH were almost identical during DSIP and placebo infusion, and the meal-related midday ACTH and cortisol surge was also unaffected. The authors concluded the data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man.
- 07Clinique humaine1994
Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep
Friedman TC, et al. · The Journal of Clinical Endocrinology and Metabolism · human diurnal sampling with concurrent polysomnography and body temperature
Plasma DSIP correlated positively with body temperature and negatively with REM and slow-wave sleep, a pattern opposite to that expected of a circulating slow-wave-sleep-promoting factor.
- 08Clinique humaine1994
Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men.
Chiodera P, et al. · Horm Res · placebo-controlled infusion study (PubMed type: randomised controlled trial), 8 healthy men aged 23-34 plus 7 further subjects; intravenous DSIP vs saline before osmotic and orthostatic stimuli
DSIP did not change circulating arginine-vasopressin at baseline or its rise after hypertonic saline or standing, but it produced a significant decrease in ACTH compared with the slight physiological decline during saline.
- 09Clinique humaine1993
Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women.
Giusti M, et al. · Psychoneuroendocrinology · controlled study, n=8 healthy women aged 17-36; intravenous DSIP, arginine and both combined (five women) and DSIP vs placebo infusion for circadian profiles (three women)
DSIP did not change basal growth hormone or prolactin, their circadian rhythm, or their responses to arginine.
- 10Clinique humaine1992
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Bes F, Hofman W, Schuur J, Van Boxtel C · Neuropsychobiology · double-blind matched-pairs parallel-group trial, n=16 chronic insomnia patients; intravenous DSIP 25 nmol/kg vs glucose placebo on three nights, polysomnography
Polysomnography showed higher sleep efficiency and shorter sleep latency with DSIP, but the effects were weak and partly attributable to change in the placebo group. The authors concluded short-term DSIP treatment of chronic insomnia was unlikely to be of major therapeutic benefit.
- 11Clinique humaine1989
Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man.
Bjartell A, et al. · Psychoneuroendocrinology · randomized double-blind crossover, n=11 healthy men, single intravenous dose
Plasma ACTH-like immunoreactivity fell for at least 3 hours after DSIP compared with saline, while plasma cortisol, urinary cortisol and urinary monoamine metabolites were unchanged.
- 12Clinique humaine1987
Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.
Schneider-Helmert D · Eur Neurol · placebo-controlled double-blind trial, n=14 middle-aged chronic insomniacs, 7 nights, polysomnography
Night sleep improved after the first and repeated administrations and the effect persisted into the first placebo night after treatment; sleep efficiency reached the level of normal controls, and daytime alertness and performance increased significantly.
- 13Clinique humaine1987
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.
Monti JM, et al. · Int J Clin Pharmacol Res · double-blind placebo-controlled crossover, chronic insomniacs, 4 nights, polysomnography
Total sleep time, NREM sleep and stage 2 increased, but differences from placebo were already present at baseline, slow-wave and REM sleep were unchanged, and the authors concluded that the sleep improvement was of little clinical significance.
- 14Clinique humaine1986
Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs.
Schneider-Helmert D · Eur Neurol · uncontrolled sleep-laboratory study, n=18 chronic psychophysiological insomniacs split into middle-aged (29-59) and older (60-83) groups; one week of intravenous DSIP and one week of follow-up
Sleep in middle-aged insomniacs improved to normal values by the end of treatment and stayed normal during follow-up; in older insomniacs, whose baseline disturbance was about twice as severe, full normalisation came only by the end of follow-up. Effects correlated with the degree of sleep disturbance; there was no placebo group.
- 15Clinique humaine1984
Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study
Larbig W, Gerber WD, Kluck M, Schoenenberger GA · European Neurology · open pilot study, n=7 patients with migraine, vasomotor headache, chronic tinnitus or psychogenic pain; intravenous DSIP over 5 consecutive days then every 48-72 h
Pain levels fell significantly in 6 of 7 patients relative to baseline, with a concurrent reduction in depressive symptoms. The design was uncontrolled and the sample very small.
- 16Clinique humaine1984
DSIP in the treatment of withdrawal syndromes from alcohol and opiates.
Dick P, et al. · Eur Neurol · open clinical series, n=107 inpatients with alcohol (n=47) or opiate (n=60) withdrawal; intravenous DSIP, no control group
Clinical withdrawal symptoms and signs disappeared or improved markedly and rapidly in 97% of evaluable opiate and 87% of evaluable alcohol patients, while anxiety decreased more slowly. Opiate patients needed more injections, and tolerance was good apart from headaches in a few patients.
- 17Clinique humaine1984
A clinical trial with DSIP.
Kaeser HE · Eur Neurol · open study, n=7 patients with severe insomnia; a series of DSIP injections, follow-up 3-7 months
Sleep normalised in all but 1 patient for follow-up periods of 3-7 months, and daytime mood and performance also improved. The author noted a long-standing habit of drug addiction as a possible problem.
- 18Clinique humaine1983
Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep
Schneider-Helmert D, Schoenenberger GA · Neuropsychobiology · five double-blind human studies with single and repeated intravenous DSIP injections, polygraphic recordings and psychophysiological tests
The authors reported a sleep-induction latency of about 1 h with effects lasting up to 20 h, normalisation of disturbed sleep in insomniacs after four consecutive injections, and increased alertness and performance during waking. Tolerability was good provided injection was slow.
- 19Clinique humaine1981
Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.
Schneider-Helmert D, et al. · Int J Clin Pharmacol Ther Toxicol · double-blind placebo-controlled crossover study, n=6 healthy volunteers (four men, two women); single morning intravenous infusion
Volunteers reported sleep pressure soon after infusion and total sleep time rose by 59% within a 130-minute interval compared with placebo; the following night showed shorter sleep onset, less stage 1 and better sleep efficiency. Behavioural and EEG analyses found no classic sedation, and no psychological, physiological or biochemical side effects were observed.
- 20Clinique humaine1981
The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.
Schneider-Helmert D, Schoenenberger GA · Experientia · clinical study, n=6 middle-aged chronic insomniacs; acute intravenous DSIP with night polygraphy
DSIP was followed by longer sleep with fewer interruptions and slightly more REM sleep, without daytime sedation or other side effects; sleep-promoting effects appeared only in the second hour after injection, after a slight arousing effect in the first hour.
- 21Animal in vivo2024
Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Mu X, Qu L, et al. · Frontiers in Pharmacology · PCPA-induced insomnia mouse model, recombinant DSIP fusion peptide expressed in Pichia pastoris
A recombinantly produced DSIP fusion peptide crossed the blood-brain barrier and produced measurable effects in a chemically induced insomnia mouse model. This is the most recent primary DSIP study indexed in PubMed.
- 22Animal in vivo2021
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
Tukhovskaya EA, et al. · Molecules · Sprague-Dawley rats, focal stroke model
DSIP administration was associated with recovery of motor function after focal stroke in rats.
- 23Animal in vivo2021
DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion
Tukhovskaya EA, et al. · Biomedicines · C57Bl/6 mice (cerebral ischaemia) and Sprague-Dawley rats (myocardial ischaemia-reperfusion)
The DSIP-like KND peptide reduced infarct size in both brain and myocardial ischaemia-reperfusion models when given during reperfusion.
- 24Animal in vivo2018
Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude
Roy K, et al. · Life Sciences · rodent model of hypobaric hypoxia / simulated high altitude
Phosphorylated DSIP improved sleep architecture and was associated with restored spatial memory performance and p-CREB expression under simulated high-altitude conditions.
- 25Animal in vivo2016
Effect of Delta Sleep-Inducing Peptide on Functional State of Hepatocytes in Rats During Restraint Stress
Bobyntsev II, et al. · Bulletin of Experimental Biology and Medicine · rat restraint-stress model, hepatocyte morphology and function
DSIP modified stress-induced changes in hepatocyte functional state, consistent with a general anti-stress rather than sleep-specific action.
- 26Animal in vivo2014
Effect of delta sleep-inducing peptide on the expression of antioxidant enzyme genes in the brain and blood of rats during physiological aging
Kutilin DS, Bondarenko TI, et al. · Bulletin of Experimental Biology and Medicine · ageing rats, brain and blood antioxidant enzyme gene expression
DSIP altered expression of antioxidant enzyme genes in brain and blood of ageing rats, forming part of the Russian geroprotection literature on this peptide.
- 27Animal in vivo2012
Effect of delta sleep-inducing peptide on oxidative modification of proteins in rat tissues and blood during physiological aging
Bondarenko TI, et al. · Bulletin of Experimental Biology and Medicine · ageing rats, protein carbonylation markers in tissues and blood
DSIP reduced markers of oxidative protein modification in ageing rats.
- 28Animal in vivo2003
Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.
Popovich IG, et al. · Mech Ageing Dev · female SHR mice, n=54 per group, lifelong monthly courses of a DSIP preparation (Deltaran) vs saline
Treatment did not change mean life span or food intake but lowered body weight, increased the life span of the longest-lived 10% and maximum life span, reduced chromosome aberrations in bone marrow, slowed age-related loss of estrous function and lowered total spontaneous tumour incidence 2.6-fold.
- 29Animal in vivo1988
Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat
Iyer KS, McCann SM · Proceedings of the National Academy of Sciences of the United States of America · rat, immunoneutralisation and administration studies of slow-wave sleep and growth hormone release
This landmark study reported evidence linking DSIP to slow-wave sleep and sleep-associated growth hormone release in the rat, and is the most frequently cited mechanistic basis for DSIP's sleep claims.
- 30Animal in vivo1977
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.
Schoenenberger GA, Monnier M · Proc Natl Acad Sci U S A · rabbits, n=58 incl. controls, double-blind intraventricular infusion of synthetic DSIP, fragments and analogues
The nonapeptide was isolated from rabbits, sequenced (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) and synthesised; of nine synthetic peptides tested, only synthetic DSIP produced significant, specific enhancement of delta and spindle EEG patterns.
- 31Revue2006
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM, Strekalova TV · Journal of Neurochemistry · critical mini-review
The authors concluded that the hypothesis of DSIP as a sleep factor is poorly documented and weak, noting that no DSIP gene, protein precursor or receptor had been isolated and that certain synthetic analogues, but not DSIP itself, promoted slow-wave sleep in rabbits and rats.
- 32Revue1984
Delta-sleep-inducing peptide (DSIP): a review
Graf MV, Kastin AJ · Neuroscience and Biobehavioral Reviews · foundational narrative review
This early review consolidated the distribution, pharmacokinetics and reported behavioural actions of DSIP, and established the framing of the peptide as multifunctional rather than sleep-specific.
- 33Rapport de cas1997
Delta sleep-inducing peptide in opioid detoxification.
Soyka M, Rothenhaeusler HB · Am J Psychiatry · case report (letter) on DSIP during opioid detoxification; details not available in the registry record
The title and publication type indicate a case report of DSIP use in opioid detoxification. Results are not available in the abstract (PubMed holds no abstract).
- 34Rapport de cas1987· German (English abstract)
[The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia].
Schneider-Helmert D, et al. · Dtsch Med Wochenschr · case report, 47-year-old woman with chronic delayed sleep phase insomnia and low-dose benzodiazepine dependence; one week of inpatient DSIP under polygraphic control
The main sleep phase advanced by 5 hours, flunitrazepam was withdrawn abruptly and completely and a normal sleep profile returned; actigraphy during the following week showed the improvement was maintained.
- 35Rapport de cas1984
Effects of DSIP on narcolepsy.
Schneider-Helmert D · Eur Neurol · case report, 35-year-old man with narcolepsy; repeated DSIP injections, polysomnography and multiple sleep latency testing
DSIP reduced the frequency of sleep attacks and increased daytime activity, alertness and performance; the night sleep period was compressed, with enhanced REM sleep.
- 36Rapport de cas1984
Sleep disturbances in a case of brain-stem lesions; pharmacological study.
Laffont F, et al. · Electroencephalogr Clin Neurophysiol · case report, severe insomnia after brain-stem lesions; slow DSIP injection compared with 5-HTP, L-DOPA and clonazepam under repeated polygraphy
Slow injection of DSIP improved sleep quantitatively and qualitatively, although paradoxical-sleep latency stayed short; the effects were reversible.
Ce que ces preuves n'établissent pas.
No DSIP receptor, gene or precursor has ever been identified, and the peptide's classification as an endogenous sleep factor is disputed in the primary literature. Human trials are small, mostly pre-1995, used intravenous rather than subcutaneous dosing, and produced inconsistent sleep outcomes; there are no modern randomised controlled trials, no pharmacokinetic characterisation for non-intravenous routes, and no controlled safety data.
Questions courantes sur la recherche.
- What is DSIP?
DSIP is a nonapeptide originally isolated from rabbit cerebral venous blood during electrically induced slow-wave sleep. It has been studied since the late 1970s and remains one of the more mechanistically unresolved peptides in the neuroscience literature.
- Does the literature explain how DSIP works?
Not conclusively. No receptor has been confirmed and no transduction pathway agreed. Reviewers describe interactions with the hypothalamic-pituitary-adrenal axis and the opioid system, plus reports on thermoregulation and gene expression, but explicitly characterise the overall picture as unresolved.
- Why does recent DSIP research have so little to do with sleep?
Because the sleep findings proved difficult to replicate. Work published since 2010 has largely moved to other endpoints — motor recovery after experimental stroke, antioxidant enzyme expression in ageing animals, and stress-model physiology — which is where the current literature sits.
Disponible dans notre catalogue
À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.